clofibrate has been researched along with Chronic Kidney Failure in 32 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased." | 2.65 | Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. ( Grützmacher, P; Lang, W; Scheuermann, E, 1981) |
| "Clofibrate treatment was shown to concomitantly decrease the liver levels of HNF1α, HNF4α and PCSK9 mRNA, as well as serum PCSK9, TAGs and total cholesterol concentrations in CRF rats." | 1.43 | Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations. ( Rutkowski, B; Sucajtys-Szulc, E; Swierczynski, J; Szolkiewicz, M, 2016) |
| "As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)." | 1.27 | Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study. ( Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients." | 1.26 | Treatment of uremic hypertriglyceridaemia with bezafibrate. ( Anderson, P; Norbeck, HE, 1982) |
| " Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7." | 1.26 | Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ( Anderson, P; Norbeck, HE, 1981) |
| " The dosage reduction from the usual clofibrate dose of 14 g/week avoided toxicity and corrected the abnormalities in serum triglyceride and high density lipoprotein cholesterol levels to or toward normal." | 1.26 | Chronic clofibrate therapy in maintenance hemodialysis patients. ( Brunzell, JD; Goldberg, AB; Haas, LB; Sherrard, DJ, 1980) |
| "It is concluded that clofibrate treatment of hyperlipidemia in uremic patients, when carefully monitored, is safe and efficacious." | 1.26 | Clofibrate treatment of hyperlipidemia in chronic renal failure. ( Boulu, R; Crosnier, J; di Giulio, S; Drüeke, T; Nicolaĭ, A; Zingraff, J, 1977) |
| " If such therapy is contemplated it must be cautiously instituted at low dosage and the patient monitored by regular assessment of serum C." | 1.25 | Clofibrate-induced muscle damage in patients with chronic renal failure. ( Alvarez-Ude, F; Kerr, DN; Pierides, AM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (93.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sucajtys-Szulc, E | 1 |
| Szolkiewicz, M | 1 |
| Swierczynski, J | 1 |
| Rutkowski, B | 1 |
| Fujioka, T | 1 |
| Ueno, T | 1 |
| Matsumoto, T | 1 |
| Watanabe, H | 1 |
| Walther, A | 1 |
| Mordasini, R | 1 |
| Riesen, W | 1 |
| Robertz, GM | 1 |
| Dengler, HJ | 1 |
| Viikari, J | 1 |
| Anttila, M | 1 |
| Kasanen, A | 1 |
| Synková, J | 1 |
| Groh, J | 1 |
| Brátová, M | 1 |
| Zahradník, J | 1 |
| Jánská, D | 1 |
| Grützmacher, P | 1 |
| Scheuermann, E | 1 |
| Lang, W | 1 |
| Lacour, B | 1 |
| Di Giulio, S | 2 |
| Nicolaï, A | 2 |
| Drüeke, T | 2 |
| Debray, M | 1 |
| Boulu, RG | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Norbeck, HE | 2 |
| Anderson, P | 2 |
| Bjornsson, TD | 1 |
| Meffin, PJ | 1 |
| Peters, FA | 1 |
| Blaschke, TF | 1 |
| Sherrard, DJ | 1 |
| Goldberg, AB | 1 |
| Haas, LB | 1 |
| Brunzell, JD | 1 |
| Jarillo, MD | 1 |
| Coca, MC | 1 |
| Díaz Rubio, C | 1 |
| Bello, I | 1 |
| Gutiérrez-Millet, V | 1 |
| Ruilope, LM | 1 |
| Rodicio, JL | 1 |
| Alvarez Ude, F | 1 |
| Pierides, AM | 1 |
| Alvarez-Ude, F | 1 |
| Kerr, DN | 1 |
| Rumpf, KW | 2 |
| Albers, R | 1 |
| Scheler, F | 2 |
| Dosa, S | 1 |
| Mallick, NP | 1 |
| Slotki, IN | 1 |
| Gabriel, R | 1 |
| Pearce, JM | 1 |
| Faed, EM | 1 |
| McQueen, EG | 1 |
| Gugler, R | 1 |
| Kürten, JW | 1 |
| Jensen, CJ | 1 |
| Klehr, U | 1 |
| Hartlapp, J | 1 |
| Boulu, R | 1 |
| Zingraff, J | 1 |
| Crosnier, J | 1 |
| Reidenberg, MM | 1 |
| Drayer, DE | 2 |
| Rieger, J | 1 |
| Doht, B | 1 |
| Ansorg, R | 1 |
| Wessels, G | 1 |
| Müller, H | 1 |
| Busch, G | 1 |
| Loew, H | 1 |
| Gibaldi, M | 1 |
| Kijima, Y | 1 |
| Sasaoka, T | 1 |
| Kanayama, M | 1 |
| Kubota, S | 1 |
| Kasiske, BL | 1 |
| O'Donnell, MP | 1 |
| Garvis, WJ | 1 |
| Keane, WF | 1 |
| Merk, W | 1 |
| Graben, N | 1 |
| Hartmann, H | 1 |
| Nikolaus, C | 1 |
| Schlierf, G | 1 |
| Schwandt, P | 1 |
| Rahn, KH | 1 |
| Radó, JP | 1 |
| Szende, L | 1 |
| Takó, J | 1 |
| Laursen, B | 1 |
| Gormsen, J | 1 |
2 reviews available for clofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
[Dyslipidemia in renal failure].
Topics: Arteriosclerosis; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronar | 2004 |
[Pharmacotherapy in chronic kidney failure].
Topics: Anti-Bacterial Agents; Antihypertensive Agents; Cardiac Glycosides; Clofibrate; Digitoxin; Digoxin; | 1974 |
1 trial available for clofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyper | 1981 |
29 other studies available for clofibrate and Chronic Kidney Failure
| Article | Year |
|---|---|
Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Topics: Actins; Animals; Apolipoprotein B-100; Body Weight; Carrier Proteins; Clofibrate; Disease Models, An | 2016 |
[Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
Topics: Clofibrate; Dietary Fats; Energy Metabolism; Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; | 1983 |
Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
Topics: Adult; Clofibrate; Clofibric Acid; Dansyl Compounds; Female; Fluorescent Dyes; Glycine; Humans; Kidn | 1983 |
The use of clofibrate in patients with renal insufficiency.
Topics: Adolescent; Adult; Aged; Blood Proteins; Clofibrate; Female; Humans; Kidney Failure, Chronic; Male; | 1983 |
[Hypolipidemic treatment in renal insufficiency].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middl | 1981 |
[Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
Topics: Binding, Competitive; Blood Proteins; Clofibrate; Clofibric Acid; Dialysis; Heparin; Humans; In Vitr | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failur | 1982 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; H | 1981 |
Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
Topics: Adult; Aged; Blood Proteins; Clofibrate; Clofibric Acid; Humans; Kidney Failure, Chronic; Middle Age | 1980 |
Chronic clofibrate therapy in maintenance hemodialysis patients.
Topics: Adult; Arteriosclerosis; Cholesterol; Clofibrate; Coronary Disease; Humans; Kidney Failure, Chronic; | 1980 |
[Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Kidney F | 1980 |
Clofibrate-induced muscle damage in patients with chronic renal failure.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Butyrates; Cholesterol; Clofibrate; Creati | 1975 |
Letter: Clofibrate-induced myopathy syndrome.
Topics: Adult; Clofibrate; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypothyroidism; Kidney | 1976 |
Letter: Acute-on-chronic renal failure precipitated by clofibrate.
Topics: Acute Kidney Injury; Adult; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Ma | 1976 |
Clofibrate-induced myopathy and neuropathy.
Topics: Adult; Clofibrate; Humans; Kidney Failure, Chronic; Male; Motor Neurons; Neuromuscular Diseases | 1976 |
Plasma half-life of clofibric acid in renal failure.
Topics: Adult; Clofibrate; Female; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; | 1979 |
Clofibrate disposition in renal failure and acute and chronic liver disease.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clofibrate; Female; Half-Life; Humans; Kidn | 1979 |
Clofibrate treatment of hyperlipidemia in chronic renal failure.
Topics: Adult; Cholesterol; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Ma | 1977 |
Drug metabolism and active drug metabolites in renal failure.
Topics: Allopurinol; Biotransformation; Clofibrate; Dose-Response Relationship, Drug; Humans; Kidney Failure | 1977 |
Drug elimination by hemofiltration.
Topics: Ampicillin; Anti-Bacterial Agents; Clofibrate; Doxycycline; Filtration; Gentamicins; Humans; Kidney | 1977 |
[Clofibrate treatment of hyperlipidemia in long-term dialysis patients].
Topics: Clofibrate; Humans; Hyperlipidemias; Kidney Failure, Chronic; Long-Term Care; Renal Dialysis | 1976 |
Drug distribution in renal failure.
Topics: Antipyrine; Clofibrate; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Kidney Failure, Ch | 1977 |
Active drug metabolites and renal failure.
Topics: Acetylation; Biotransformation; Clofibrate; Humans; Kidney Failure, Chronic; Meperidine; Methyldopa; | 1977 |
Clofibrate effect on alkaline phosphatase in renal failure.
Topics: Alkaline Phosphatase; Bone and Bones; Clofibrate; Humans; Hyperlipidemias; Isoenzymes; Kidney Failur | 1977 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Topics: Adult; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Kidney Failure, Chronic; Kinetics; Ma | 1987 |
Drug-induced inhibition of the diuretic response to water loading in partial vasopressin responsive nephrogenic diabetes insipidus.
Topics: Adult; Carbamazepine; Clofibrate; Diabetes Insipidus; Diuresis; Female; Glomerular Filtration Rate; | 1974 |
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu | 1969 |